L-Phenylalanine
|
Basic information |
| Metabolite name | L-Phenylalanine |
 | HMDB0000159 |
 |
C00079 |
 |
6140 |
| Synonyms | phenylalanie; |
| No. of studies | 99 |
|
Basic information |
| Metabolite name | L-Phenylalanine |
| HMDB0000159 |
|
C00079 |
|
6140 |
| Synonyms | phenylalanie; |
| No. of studies | 99 |
|
Relationship between L-Phenylalanine and depression (count: 99) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + QZ group vs. CUMS group | Urine | Wistar rat | Down |
| Study M031 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M048 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M048 | Type1 | CVS group vs. control group | Serum | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Serum | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Serum | Wistar rat | Down |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M062 | Type1 | CUMS group vs. control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Down |
| Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M072 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M078 | Type1 | CORT model group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Serum | Sprague-Dawley rat | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M090 | Type1 | depressed group vs. control group | Urine | Human | Down |
| Study M090 | Type2 | depressed group 6-week treatment vs. baseline | Urine | Human | Up |
| Study M094 | Type1 | PSD group vs. stroke and control group | Urine | Human | Up |
| Study M095 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Down |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M1004 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Up |
| Study M1004 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Down |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Ileum | Sprague-Dawley rat | Down |
| Study M1004 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1023 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1045 | Type1 | anxiety and depression group vs. control group | Plasma | Human | Up |
| Study M1054 | Type1 | CUMS group vs. control group | Plasma | ICR mouse | Down |
| Study M1054 | Type2 | CUMS + ChaihuYujinxiang granules group vs. CUMS group | Plasma | ICR mouse | Up |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M1079 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1086 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Down |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + moderate dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M146 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Down |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M544 | Type1 | PSD group vs. stoke group | Plasma | Human | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M610 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M636 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M636 | Type2 | CUMS + Shugan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Down |
| Study M674 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M674 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M676 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M676 | Type2 | CVS + antibiotic group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M676 | Type2 | CVS + Chaihu-Shu-Gan-San group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Chaihu group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M750 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Down |
| Study M757 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M809 | Type2 | CUMS + Milletia speciosa Champ group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Down |
| Study M828 | Type2 | ultrasonic radiation + intranasally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M870 | Type2 | CRS + sertraline group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M877 | Type1 | depressed COPD group vs. COPD group | Plasma | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M905 | Type1 | subclinical depression group vs. control group | Urine | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M909 | Type3 | ketamine group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M924 | Type2 | CUMS + aerobic exercise group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M927 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M927 | Type2 | CUMS + Zhi-zi-chi decoction group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M940 | Type2 | CUMS + Chaihu-Baishao herb pair group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |